Pembrolizumab: all 1,753 studies that test it

Page 1 of 18. Open to participants first (418), then studies with results posted, then the rest; newest registration first within each.

• A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]RecruitingNCT07890714Phase 1/2
• Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid CancerNot yet recruitingNCT07886905Phase 2
• A Study of Treatment Delivery Preference In People With Kidney CancerRecruitingNCT07872553Phase 4
• US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and ChemotherapyNot yet recruitingNCT07862751Phase 2
• Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast CancerNot yet recruitingNCT07857486Phase 2
• Histotripsy in Biliary Tract CancerRecruitingNCT07853690Not applicable
• A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract CancerRecruitingNCT07850791Phase 2
• Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)Not yet recruitingNCT07845786Phase 2
• A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor MonotherapyNot yet recruitingNCT07843550Phase 1/2
• Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP TrialNot yet recruitingNCT07840456Phase 2
• Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell CarcinomaNot yet recruitingNCT07840001Phase 2
• A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)Not yet recruitingNCT07829783Phase 3
• A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial CancerNot yet recruitingNCT07822373Phase 2
• Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Combination Therapy With Pembrolizumab and Irinotecan in Patients With Metastatic or Recurrent Malignant MelanomaNot yet recruitingNCT07817901Phase 1/2
• Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon CancerRecruitingNCT07808151Phase 2
• A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCCRecruitingNCT07807163Phase 2
• A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung CancerNot yet recruitingNCT07802821Phase 3
• Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBCNot yet recruitingNCT07786428Phase 2
• Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)RecruitingNCT07770100Phase 2
• A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult ParticipantsRecruitingNCT07756645Phase 3
• Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual DiseaseRecruitingNCT07750158Phase 3
• A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsRecruitingNCT07749586Phase 1/2
• A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)RecruitingNCT07743190Phase 2
• NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) MelanomaRecruitingNCT07740941Phase 2
• A Study of DS-3939a in Participants With Solid TumorsNot yet recruitingNCT07739966Phase 1/2
• Open-Label Neoadjuvant Pembrolizumab Plus Cetuximab in Betel Nut-Associated Locally Advanced Oral Cavity Squamous Cell CarcinomaNot yet recruitingNCT07733466Phase 2
• RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck CancerNot yet recruitingNCT07732634Phase 2
• Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell CancerRecruitingNCT07718854Phase 2
• EWSR1 Immunotherapy in Ewing Sarcoma and DSRCTNot yet recruitingNCT07695311Phase 1
• A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizumab in Subjects With Resectable Clear Cell Renal Cell CarcinomaNot yet recruitingNCT07691476Phase 2
• Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell CarcinomaNot yet recruitingNCT07689240Phase 3
• Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell CancerNot yet recruitingNCT07680088Phase 2
• Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial CancerRecruitingNCT07667335Phase 1/2
• Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)RecruitingNCT07660094Phase 3
• Sitagliptin With Pembro in RCC and MelanomaRecruitingNCT07634380Phase 1
• A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic CholangiocarcinomaNot yet recruitingNCT07632235Phase 1/2
• Study of Peripheral Neuropathy in Patients With Advanced Urothelial Cancer Treated With Enfortumab Vedotin and Pembrolizumab With Supportive Neuridase (ENDEAVOR)Not yet recruitingNCT07629700Not applicable
• A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving PembrolizumabRecruitingNCT07619599Phase 1
• Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER TrialNot yet recruitingNCT07610525Phase 2
• Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy MaintenanceRecruitingNCT07594015Phase 2
• A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal CancerNot yet recruitingNCT07591597Phase 1/2
• Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)RecruitingNCT07566156Phase 3
• The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III MelanomaRecruitingNCT07565285Phase 2
• Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)Not yet recruitingNCT07552558Phase 1/2
• A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)RecruitingNCT07513376Phase 3
• Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck CancerRecruitingNCT07501650Phase 1
• Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without PembrolizumabRecruitingNCT07486817Phase 2
• Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus ChemotherapyNot yet recruitingNCT07486687Phase 3
• H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)Not yet recruitingNCT07484139Phase 2
• Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial CancerRecruitingNCT07484022Phase 1
• A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderRecruitingNCT07475806Phase 2
• BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid TumorsRecruitingNCT07469774Phase 1/2
• Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver MetastasesNot yet recruitingNCT07466927Phase 2
• Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCCRecruitingNCT07465276Phase 2
• Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatmentNot yet recruitingNCT07460206Phase 2
• Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell CarcinomasRecruitingNCT07455032Phase 1
• QLS5132 Combination Therapy in Advanced Solid TumorsNot yet recruitingNCT07453394Phase 1/2
• ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung CancerRecruitingNCT07452224Phase 2
• A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma.RecruitingNCT07448831Phase 2
• Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in SloveniaRecruitingNCT07422779Not applicable
• Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung DiseaseNot yet recruitingNCT07420439Phase 2
• A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesRecruitingNCT07415031Phase 2
• EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid TumorsRecruitingNCT07410676Phase 1/2
• Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon CancerNot yet recruitingNCT07409844Phase 2
• Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR TrialRecruitingNCT07407920Phase 2
• 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory TumorsRecruitingNCT07404332Phase 1
• Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)Not yet recruitingNCT07388550Phase 1
• Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair DeficiencyNot yet recruitingNCT07385846Phase 1
• Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix CancerNot yet recruitingNCT07368985Phase 2
• Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 LevelsRecruitingNCT07360743Phase 2
• Neoadjuvant Pembrolizumab in Patients With Stage IIb/c MelanomaRecruitingNCT07349303Phase 2
• Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT GlioblastomaNot yet recruitingNCT07347210Phase 2
• Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive SurgeryRecruitingNCT07343596Not applicable
• Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null PhenotypeRecruitingNCT07341867Phase 1
• A Study of KN026-based Combination Therapy in HER2-positive Gastric CancerNot yet recruitingNCT07332533Phase 2/3
• A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)RecruitingNCT07302347Phase 1/2
• GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 AstrocytomaRecruitingNCT07301268Phase 2
• Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01RecruitingNCT07290894Phase 2
• Amping up With PemJAKRecruitingNCT07283822Phase 2
• Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue SarcomaRecruitingNCT07283731Phase 2
• Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver CancerNot yet recruitingNCT07282509Phase 1/2
• Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentRecruitingNCT07275216Phase 2
• A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLCRecruitingNCT07264816Phase 2
• EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) TumorsRecruitingNCT07262619Phase 1/2
• A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PCRecruitingNCT07255664Phase 1/2
• Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate CancerRecruitingNCT07244393Phase 1
• KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)RecruitingNCT07232602Phase 1/2
• A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other TherapiesRecruitingNCT07231458Phase 1
• Patient Preference for Subcutaneous vs. Intravenous Immune TherapyRecruitingNCT07223424Phase 2
• Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial CarcinomaRecruitingNCT07221942Phase 2
• A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4Enrolling by invitationNCT07218003Phase 1
• N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerNot yet recruitingNCT07217496Phase 1
• Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid TumorsRecruitingNCT07215637Phase 1
• A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.RecruitingNCT07207395Phase 2
• Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerRecruitingNCT07198074Phase 3
• A Study of YL242 in Subjects With Advanced Solid TumorsRecruitingNCT07197827Phase 1/2
• Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast CancerRecruitingNCT07188246Phase 2
• Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)RecruitingNCT07187778Phase 2
• Circulating Tumor DNA Response In Urothelial CancerRecruitingNCT07183319Phase 2
• NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast CancerNot yet recruitingNCT07178730Phase 3

← Pembrolizumab overview